Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

par Fujii, T., Kogawa, T., Dong, W., Sahin, A. A., Moulder, S., Litton, J. K., Tripathy, D., Iwamoto, T., Hunt, K. K., Pusztai, L., Lim, B., Shen, Y., Ueno, N. T.
Publié dans Ann Oncol (2017)

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

par Bayraktar, S., Gutierrez-Barrera, A. M., Lin, H., Elsayegh, N., Tasbas, T., Litton, J. K., Ibrahim, N. K., Morrow, P. K., Green, M., Valero, V., Booser, D. J., Hortobagyi, G. N., Arun, B. K.
Publié 2013

Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation

par Litton, J.K., Westin, S.N., Ready, K., Sun, C.C., Peterson, S.K., Meric-Bernstam, F., Gonzalez-Angulo, A.M., Bodurka, D.C, Lu, K.H., Hortobagyi, G.N., Arun, B.K.
Publié 2009

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

par Kim, M. M., Allen, P., Gonzalez-Angulo, A. M., Woodward, W. A., Meric-Bernstam, F., Buzdar, A. U., Hunt, K. K., Kuerer, H. M., Litton, J. K., Hortobagyi, G. N., Buchholz, T. A., Mittendorf, E. A.
Publié 2013

Effect of Age and Race Upon Quality of Life of Young Breast Cancer Survivors

par Morrow, P.K., Broxson, A.C., Munsell, M.F., Basen-Enquist, K., Rosenblum, C.K., Schover, L.R., Nguyen, L.H., Hsu, L., Castillo, L., Hahn, K.M.E., Litton, J.K., Mattair, D.M., Hortobagyi, G.N.
Publié 2013

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

par Mittendorf, E. A., Ardavanis, A., Symanowski, J., Murray, J. L., Shumway, N. M., Litton, J. K., Hale, D. F., Perez, S. A., Anastasopoulou, E. A., Pistamaltzian, N. F., Ponniah, S., Baxevanis, C. N., von Hofe, E., Papamichail, M., Peoples, G. E.
Publié dans Ann Oncol (2016)

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

par McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.
Publié dans Ann Oncol (2021)

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer

par Chen, J. Q., Bao, Y., Lee, J., Murray, J. L., Litton, J. K., Xiao, L., Zhou, R., Wu, Y., Shen, X. Y., Zhang, H., Sahin, A. A., Katz, R. L., Bondy, M. L., Berinstein, N. L., Hortobagyi, G. N., Radvanyi, L. G.
Publié 2013

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

par Litton, J. K., Scoggins, M., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., Gomez, J. Schwartz, Mittendorf, E. A., Thompson, A., Helgason, T., Mills, G. B., Piwnica-Worms, H., Arun, B. K.
Publié dans NPJ Breast Cancer (2017)

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in wom...

par Gonzalez-Angulo, A. M., Akcakanat, A., Liu, S., Green, M. C., Murray, J. L., Chen, H., Palla, S. L., Koenig, K. B., Brewster, A. M., Valero, V., Ibrahim, N. K., Moulder-Thompson, S., Litton, J. K., Tarco, E., Moore, J., Flores, P., Crawford, D., Dryden, M. J., Symmans, W. F., Sahin, A., Giordano, S. H., Pusztai, L., Do, K-A., Mills, G. B., Hortobagyi, G. N., Meric-Bernstam, F.
Publié 2014